Printer Friendly

STEVE E. REESE JOINS CYTOMED AS VICE PRESIDENT, BUSINESS DEVELOPMENT

STEVE E. REESE JOINS CYTOMED AS VICE PRESIDENT, BUSINESS DEVELOPMENT
 CAMBRIDGE, Mass., July 27 /PRNewswire/ -- CytoMed, Inc. announced today that Steve E. Reese has been appointed vice president, business development. Reese has 15 years of marketing and business development experience in the pharmaceutical industry including over seven years with Squibb Corporation and Bristol-Myers Squibb.
 "Steve Reese brings to CytoMed significant U.S. and international pharmaceutical marketing expertise as well as extensive staff development and training skills," commented Thomas R. Beck, M.D., CytoMed chairman and chief executive officer. "Steve led the teams responsible for developing marketing and launching strategies for Bristol-Myers Squibb's recently approved cholesterol-lowering drug Pravachol (pravastatin). At CytoMed he will play a major role setting product development and forging strategic alliances worldwide. We are pleased to welcome him to our firm."
 Reese, 43 was previously president, pharmaceutical division and chief operating officer at Competence Assurance Systems, Inc. of Cambridge, Mass. From 1982 to 1989 Reese held a variety of senior management positions at Bristol-Myers Squibb and Squibb Corporation in marketing and business development. He holds a B.S. degree in pharmacy from the University of Oklahoma.
 CytoMed's product development efforts are focused on generating novel therapies to block and neutralize the mediators involved in producing an inflammatory or immune response. The company's products will address major, growing markets including autoimmune diseases and anti-inflammatory therapies. CytoMed, a private pharmaceutical company, is headquartered in Cambridge, Mass.
 -0- 7/27/92
 /CONTACT: Thomas R. Beck, M.D. of CytoMed, 617-661-3400, or Lynne H. Brum of Feinstein Partners, 617-577-8110, for CytoMed/ CO: CytoMed ST: Massachusetts IN: MTC SU: PER


CH -- NE005 -- 3367 07/27/92 09:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1992
Words:276
Previous Article:MINNOVA TO BE ACQUIRED BY METALL
Next Article:MOHAWK INDUSTRIES TO ACQUIRE HORIZON INDUSTRIES
Topics:


Related Articles
CYTOMED PROMOTES MICHAEL E. FITZGERALD TO VICE PRESIDENT, CHIEF FINANCIAL OFFICER
CYTOMED, INC. EXPANDS SCIENTIFIC TEAM -- ADDS SENIOR DIRECTOR, MEDICINAL CHEMISTRY AND PRINCIPAL SCIENTIST
CYTOMED AND GRELAN PHARMACEUTICAL ENTER COLLABORATION TO DEVELOP TOPICAL DERMATOLOGIC COMPOUNDS
TO BUSINESS AND TECHNOLOGY EDIOTRS:
CytoMed Appoints Richard Woodrich Executive Vice President and COO
American Biogenetic Sciences Inc. Appoints Stephen H. Ip, Ph.D, Executive Vice President and Chief Operating Officer
CytoMed Initiates Phase II Clinical Trials of CMI-392 for the Treatment of Psoriasis
James P. Feeney Joins Vertex Pharmaceuticals as Senior Director of Business Development
CytoMed Appoints Grace Yeh, Ph.D. As Chief Scientific Officer.
Therion Appoints Richard Woodrich as Senior Vice President, Business Development.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters